Barclays
AVBP icon

Barclays’s ArriVent BioPharma AVBP Stock Holding History

Barclays’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Sell
65,408
-63,765
-49% -$1.44M ﹤0.01% 2523
2025
Q4 		$2.6M Sell
129,173
-762
-0.6% -$15.9K ﹤0.01% 2740
2025
Q3 		$2.4M Buy
129,935
+12,723
+11% +$250K ﹤0.01% 2759
2025
Q2 		$2.55M Buy
117,212
+76,629
+189% +$1.59M ﹤0.01% 2666
2025
Q1 		$750K Sell
40,583
-12,916
-24% -$316K ﹤0.01% 3279
2024
Q4 		$1.43M Buy
53,499
+11,977
+29% +$344K ﹤0.01% 3141
2024
Q3 		$976K Buy
41,522
+38,132
+1,125% +$866K ﹤0.01% 3377
2024
Q2 		$62.9K Sell
3,390
-10,818
-76% -$193K ﹤0.01% 4117
2024
Q1 		$254K Buy
+14,208
New +$287K ﹤0.01% 3985

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's AVBP Position: Q1 2026 in Review

Barclays reduced its ArriVent BioPharma (AVBP) stake by 49% in Q1 2026, selling an estimated $1.44M and leaving 65,408 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2523.

Barclays first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.6M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Barclays held 65,408 shares of ArriVent BioPharma worth $1.51M as of Q1 2026.
  • Barclays sold 63,765 ArriVent BioPharma shares in Q1 2026, an estimated $1.44M.
  • ArriVent BioPharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2523 holding.
  • Barclays first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Barclays's ArriVent BioPharma position peaked at $2.6M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.